The Department of Health and Human Services has announced more than $500 million in awards to support companies as they move their vaccine candidates to Phase 2b clinical trials and further develop new technologies as part of Project NextGen.
Project NextGen is a $5 billion government initiative that seeks to speed up the development of next-generation vaccines and other treatments through public-private partnerships.
HHS said Friday CastleVax, Codagenix and Gritstone Bio will receive $28 million in awards to continue work on their vaccines.
CastleVax is developing a vector-based intranasal vaccine candidate, while Codagenix is working on a live-attenuated intranasal vaccine. Gritsone Bio’s candidate is a self-amplifying mRNA vaccine.
The Biomedical Advanced Research and Development Authority is awarding $240 million to support the development of technologies in the areas of genomic sequencing, cold-chain sample management and laboratory testing capacity and another $241 million to assist companies working on monoclonal antibodies and technologies that could be used in virus testing and vaccine administration.
The recipients and the amount of their respective awards are listed below:
- American Type Culture Collection – $87 million
- BioInfoExperts – $4 million
- PPD – $126.5 million
- Vir Biotechnology – $40 million
- Luminary Labs – $100 million
- ModeX Therapeutics – $59 million
- Draper – $10.5 million
- Battelle – $6.1 million
- U.K. Health Security Agency – $5.8 million
- Evidation – $20 million
- Meso Scale Diagnostics – $23.2 million
Find out the latest health care technology trends at the Potomac Officers Club’s 2023 Healthcare Summit on Dec. 6. Register here to attend this important event.
